Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.90 +0.6%	$6.03	$3.93 ▼ $7.32	$300.29M	1.51	695,611 shs	372,932 shs
CLNN Clene	$3.94 -0.4%	$3.41	$2.28 ▼ $7.00	$35.48M	0.55	90,588 shs	32,788 shs
GLSI Greenwich LifeSciences	$10.04 +1.6%	$9.56	$8.06 ▼ $17.19	$132.08M	1.63	43,470 shs	31,423 shs
ZVRA Zevra Therapeutics	$9.79 +4.0%	$8.57	$4.20 ▼ $10.03	$514.53M	1.97	685,187 shs	1.18 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+5.39%	-1.84%	-6.53%	+18.59%	+42.48%
CLNN Clene	+1.28%	-3.66%	-19.39%	+29.51%	-40.33%
GLSI Greenwich LifeSciences	+9.17%	+9.78%	+2.49%	+6.81%	-43.80%
ZVRA Zevra Therapeutics	+5.14%	+0.86%	+8.66%	+26.65%	+115.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	4.0394 of 5 stars	3.5	2.0	4.5	1.9	2.5	0.0
CLNN Clene	2.8275 of 5 stars	3.6	2.0	0.0	2.5	2.5	0.6
GLSI Greenwich LifeSciences	1.9317 of 5 stars	3.5	0.0	0.0	2.2	3.3	0.0
ZVRA Zevra Therapeutics	2.3968 of 5 stars	3.6	3.0	0.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	226.05% Upside
CLNN Clene	3.17	Buy	$40.00	916.52% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	288.64% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.14	136.51% Upside

Current Analyst Ratings Breakdown

Latest CLNN, ZVRA, GLSI, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/30/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	86.30	N/A	N/A	$1.01 per share	5.85
CLNN Clene	$340K	103.93	N/A	N/A	($1.06) per share	-3.71
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
ZVRA Zevra Therapeutics	$23.61M	22.66	N/A	N/A	$0.74 per share	13.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	8/6/2025 (Estimated)
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	48.93	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest CLNN, ZVRA, GLSI, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
CLNN Clene	N/A	1.36	1.36
GLSI Greenwich LifeSciences	N/A	1.91	1.91
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CLNN Clene	23.28%
GLSI Greenwich LifeSciences	4.16%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
CLNN Clene	35.30%
GLSI Greenwich LifeSciences	51.67%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	N/A	51.16 million	47.63 million	Optionable
CLNN Clene	100	8.98 million	5.81 million	Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

CLNN, ZVRA, GLSI, and ABEO Headlines

Recent News About These Companies

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 5.9% - Still a Buy?

July 3 at 12:48 PM | marketbeat.com

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

July 3 at 9:21 AM | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at HC Wainwright

July 2 at 8:44 AM | marketbeat.com

Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $22.29

June 23, 2025 | americanbankingnews.com

Carret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 21, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

June 20, 2025 | marketbeat.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC

June 3, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 13, 2025 | taiwannews.com.twT

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN, ZVRA, GLSI, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.90 +0.03 (+0.58%)

Closing price 03:18 PM Eastern

Extended Trading

$5.90 -0.01 (-0.15%)

As of 04:39 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Clene NASDAQ:CLNN

$3.94 -0.02 (-0.38%)

Closing price 01:04 PM Eastern

Extended Trading

$3.94 0.00 (0.00%)

As of 04:58 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Greenwich LifeSciences NASDAQ:GLSI

$10.04 +0.16 (+1.57%)

As of 03:12 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Zevra Therapeutics NASDAQ:ZVRA

$9.78 +0.38 (+3.99%)

Closing price 03:52 PM Eastern

Extended Trading

$9.54 -0.24 (-2.45%)

As of 04:48 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time